STOCK TITAN

TG Therapeutics, Inc. - TGTX STOCK NEWS

Welcome to our dedicated page for TG Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics stock.

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company headquartered in New York City, dedicated to developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. The company has a rich pipeline of products aimed at addressing unmet medical needs in these areas.

One of TG Therapeutics' flagship products is BRIUMVI® (ublituximab-xiiy), a novel monoclonal antibody targeting CD20-expressing B-cells. BRIUMVI is FDA-approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company has also received approval from the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of RMS in Europe and the United Kingdom, respectively.

In addition to BRIUMVI, TG Therapeutics is advancing several other therapies:

  • TG-1701 (BTK inhibitor)
  • TG-1801 (anti-CD47/CD19 bispecific mAb)
, targeting B-cell disorders in Phase 1 trials. The company is also working on TG-1101 (ublituximab) and TGR-1202 (umbralisib), both in clinical development for hematologic malignancies.

Recent company news highlights the robust clinical activity of BRIUMVI, as demonstrated in the ULTIMATE I & II Phase 3 trials, and the company’s ongoing commitment to the multiple sclerosis community. TG Therapeutics has also been awarded a national contract with the Department of Veterans Affairs (VA) to list BRIUMVI as the preferred agent on the VA National Formulary for Anti-CD20 Antibody indications.

Financially, TG Therapeutics reported strong first-quarter 2024 sales, with BRIUMVI U.S. net revenue exceeding $50 million, leading to revised annual guidance of $270 to $290 million for 2024. The company is focused on expanding its commercial infrastructure and advancing its research pipeline, including developing a subcutaneous form of BRIUMVI and moving the therapy into additional indications beyond MS.

For more information, visit the company’s website at www.tgtherapeutics.com.

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) presented updated data from the ENHANCE Phase 3b trial of BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the 2024 ECTRIMS meeting. Key findings include:

1. Patients switching from prior anti-CD20 treatment can successfully eliminate the initial BRIUMVI infusion.

2. Rapid 30-minute BRIUMVI infusions are well-tolerated, with only mild (Grade 1) infusion-related reactions.

3. 97% of 1-hour infusions for B-cell depleted patients were completed without interruption.

4. 12 patients received 30-minute infusions at week 24, all completed without interruption.

The company aims to improve patient tolerability and convenience, potentially leading to label-enabling studies for optimized dosing regimens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) presented updated 5-year data from the ULTIMATE I & II Phase 3 trials of BRIUMVI® (ublituximab-xiiy) in relapsing multiple sclerosis (RMS) at the 2024 ECTRIMS meeting. Key findings include:

- 92% of patients were free from disability progression after 5 years of BRIUMVI treatment
- Annualized relapse rate in year 5 was 0.020 (1 relapse per 50 patient-years)
- Safety profile remained consistent over 5 years with no new signals
- Patients who switched from teriflunomide to BRIUMVI saw a 58.4% reduction in relapse rate
- 17% of patients on continuous BRIUMVI achieved confirmed disability improvement

The data support BRIUMVI as a valuable long-term treatment option for RMS patients, demonstrating sustained clinical efficacy and a tolerable safety profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced upcoming data presentations for BRIUMVI (ublituximab-xiiy) at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The presentations will highlight data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial, evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis (RMS).

The meeting will be held from September 18-20, 2024, in Copenhagen, Denmark. Three poster presentations are scheduled, covering topics such as five-year results of ublituximab in RMS, efficacy and tolerability after transitioning from different therapies, and comparison of Multiple Sclerosis Disease Activity (MSDA) Test results between ublituximab and teriflunomide treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
none
Rhea-AI Summary

HealthCare Royalty (HCRx) and Blue Owl Capital have provided a $250 million term loan facility to TG Therapeutics (NASDAQ: TGTX), a biopharmaceutical company focused on B-cell diseases. The loan, maturing on August 2, 2029, supports TG's commercialization of BRIUMVI®, an anti-CD20 monoclonal antibody for treating relapsing forms of multiple sclerosis. BRIUMVI® generated $89 million in U.S. net revenue in 2023. An additional $100 million facility is available at mutual option. This financing demonstrates confidence in TG Therapeutics' commercial progress and provides capital for its business objectives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) reported strong Q2 2024 financial results, with U.S. BRIUMVI net revenue of $72.6 million, representing over 350% growth year-over-year. The company raised its full-year 2024 U.S. BRIUMVI net revenue guidance to $290-$300 million. TG Therapeutics achieved positive cash flow in Q2 2024 and established a $250 million credit facility to repay existing debt and initiate a share repurchase program. The company also made progress in its R&D pipeline, initiating a phase 1 study for subcutaneous ublituximab in RMS patients and receiving FDA IND clearance for azer-cel in progressive MS. With approximately 5,850 new patient prescriptions for BRIUMVI since launch, TG Therapeutics continues to show strong commercial momentum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.58%
Tags
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced a conference call scheduled for Tuesday, August 6, 2024, at 8:30 AM ET to discuss the company's second quarter 2024 financial results and provide a business outlook for 2024. The call will be hosted by Michael S. Weiss, Chairman and CEO. Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside U.S.). A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days after the call. TG Therapeutics will release its financial results in a press release prior to the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
conferences earnings
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, held at the Loews Miami Beach Hotel, from June 10-13, 2024.

Weiss is scheduled for a fireside chat on June 11, 2024, at 1:20 PM ET. A live webcast will be available on the company's Investors & Media section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) will participate in the Jefferies Global Healthcare Conference on June 5-6, 2024, at the Marriott Marquis, New York City. Michael S. Weiss, Chairman and CEO, will conduct a fireside chat on June 5, 2024, at 1:30 PM ET. The event will be webcast live and accessible on TG Therapeutics' website.

The conference appearance aims to provide updates on the company's progress and strategies, potentially impacting investor perception and stock performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
conferences
-
Rhea-AI Summary

TG Therapeutics presented study designs for post-marketing studies of BRIUMVI® (ublituximab) at the 2024 Consortium of Multiple Sclerosis Centers annual meeting. The studies focus on evaluating BRIUMVI's presence in breast milk and its impact on pregnancy and infant outcomes. These presentations are now publicly available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
none
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced the schedule for upcoming presentations regarding BRIUMVI® (ublituximab) at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, set to take place from May 29 to June 1 in Nashville, Tennessee.

The presentations will highlight post-marketing studies on BRIUMVI for patients with relapsing forms of multiple sclerosis (RMS). Key sessions include:

- 'A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI in Breast Milk' scheduled for May 30, led by Dr. Riley Bove from UCSF.

- 'BRIUMVI Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI' also on May 30, led by Dr. Riley Bove from UCSF.

Abstracts are available online on the CMSC meeting website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences

FAQ

What is the current stock price of TG Therapeutics (TGTX)?

The current stock price of TG Therapeutics (TGTX) is $25.06 as of October 31, 2024.

What is the market cap of TG Therapeutics (TGTX)?

The market cap of TG Therapeutics (TGTX) is approximately 3.4B.

What is TG Therapeutics' primary focus?

TG Therapeutics focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases.

What is BRIUMVI?

BRIUMVI (ublituximab-xiiy) is a monoclonal antibody targeting CD20-expressing B-cells, approved for treating relapsing forms of multiple sclerosis (RMS).

Where is TG Therapeutics headquartered?

The company is headquartered in New York City.

What recent financial performance did TG Therapeutics report?

The company reported over $50 million in BRIUMVI U.S. net revenue for Q1 2024 and updated its annual guidance to $270 to $290 million.

Has BRIUMVI received regulatory approvals outside the U.S.?

Yes, BRIUMVI has been approved by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for RMS treatment in Europe and the UK.

What other therapies is TG Therapeutics developing?

TG Therapeutics is also developing TG-1701, TG-1801, TG-1101 (ublituximab), and TGR-1202 (umbralisib) for B-cell disorders and hematological malignancies.

What are the ULTIMATE I & II Phase 3 trials?

The ULTIMATE I & II trials are clinical studies evaluating the efficacy of BRIUMVI in treating relapsing forms of multiple sclerosis.

What support programs does TG Therapeutics offer for BRIUMVI?

TG Therapeutics offers BRIUMVI Patient Support, a flexible program designed to assist U.S. patients through their treatment journey.

What is the significance of TG Therapeutics' national contract with the VA?

The contract makes BRIUMVI the preferred anti-CD20 antibody therapy for RMS on the VA National Formulary, enhancing access for veterans.

Where can more information about TG Therapeutics be found?

More information is available on the company's website at www.tgtherapeutics.com.

TG Therapeutics, Inc.

Nasdaq:TGTX

TGTX Rankings

TGTX Stock Data

3.40B
154.82M
9.59%
61.21%
20.98%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK